Clonal hematopoiesis, cardiovascular events and treatment benefit in 63,700 individuals from five TIMI randomized trials
Year: 2024
Type: article
Source: Nature Medicine
Authors: Nicholas A. Marston, James P. Pirruccello, Giorgio E. M. Melloni, Frederick Kamanu, Marc P. Bonaca, Robert P. Giugliano, Benjamin M. Scirica, Stephen D. Wiviott, Deepak L. Bhatt, Philippe Gabriel Steg, Itamar Raz, Eugene Braunwald, Peter Libby, Patrick T. Ellinor, Alexander G. Bick, Marc S. Sabatine, Christian T. Ruff
Institutions: Brigham and Women's Hospital, Harvard University, Thrombolysis in Myocardial Infarction Study Group, University of California, San Francisco, Mount Sinai Health System, Icahn School of Medicine at Mount Sinai, Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hadassah Medical Center, Broad Institute, Massachusetts General Hospital, Vanderbilt University Medical Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: American Heart Association, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Bayer, Sanofi, Brigham and Women's Hospital, Massachusetts General Hospital, FibroGen, CSL Behring, Regeneron Pharmaceuticals, Intarcia Therapeutics, Quest Diagnostics, Kowa Company, MyoKardia, Belvoir Media Group, Moderna, Zora Biosciences, ARCA Biopharma, Daiichi-Sankyo, Eisai, Novo Nordisk, Silence Therapeutics, Esperion Therapeutics, National Institutes of Health, Genentech, National Heart, Lung, and Blood Institute, Janssen Research and Development, Duke Clinical Research Institute, Daiichi Sankyo Europe
Awards: G4463822314, Risk Prediction and Personalizing Therapy to Prevent Critical Limb ischemia in Patients with PAD and Diabetes, Discovery and Application of Germline and Somatic Mutations for Risk Prediction and Personalized Therapy to Prevent Recurrent Myocardial Infarction, Deep learning to enable the genetic analysis of aorta
OpenAlex ID: W4401368380